发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
:No data are available on the surgical safety of radical cystectomy (RC) and pelvic lymph node dissection (PLND) after the administration of checkpoint inhibitors. We aimed at reporting the first prospective rigorous assessment of perioperative outcomes after RC and extended PLND following neoadjuvant pembrolizumab in a contemporary cohort of patients with muscle-invasive bladder cancer (MIBC) enrolled in the PURE-01 trial. From February 2017 to June 2019, a total of 68 consecutive patients who received three courses of 200 mg pembrolizumab intravenously every 3 wk and were subsequently treated with either open or robot-assisted RC and PLND at a single high-volume tertiary referral center were identified. All men had prospectively collected data about intra- and postoperative outcomes. Postoperative complications were graded according to the Clavien-Dindo system. Perioperative data were prospectively and systematically collected during patient interviews at 90 d after surgery according to the European Association of Urology (EAU) Guidelines Panel recommendations on reporting and grading complications. Overall, 52 (77%) versus 16 (23%) patients underwent robot-assisted versus open RC, and 31 patients (46%) received an orthotopic neobladder. Median blood loss and length of stay were 150 ml and 12 d, respectively. Overall, 52 (77%), 47 (69%), and 22 (32%) patients experienced any-grade complications, grade ≥2 complications, and readmission at 90 d, respectively. High-grade complications (defined as Clavien-Dindo ≥3a) were observed in 23 patients (34%). The most frequent complications were fever (n = 35, 52%) and ileus (n = 21, 31%). None of the patients experienced perioperative mortality at 90 d. Our data represent the first prospective evidence supporting the surgical safety of RC and PLND in patients with N0M0 MIBC who received neoadjuvant immunotherapy with pembrolizumab. PATIENT SUMMARY: The current study represents the first prospective evidence supporting the surgical safety of radical cystectomy and pelvic lymph node dissection in patients with nonmetastatic bladder cancer who received neoadjuvant immunotherapy with pembrolizumab.
展开更多
最新影响因子:24.267 | 期刊ISSN:0302-2838 | CiteScore:6.93 |
出版周期:Monthly | 是否OA:YES | 出版年份:1975 |
自引率:6.60% | 研究方向:医学-泌尿学与肾脏学 |
出版地区:NETHERLANDS |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
Each issue of ëEuropean Urologyí contains twenty to thirty original articles on a wide range of urological problems. Carefully selected peer-reviewed articles offer useful information on such topics as oncology, impotence, infertility, pediatrics, lithiasis and endourology. Recent advances in techniques, instrumentation, surgery and pediatric urology are supported by topical reviews and papers on applied research to provide readers with a complete guide to international developments in urology. The journalís value as a practical reference for all urologists is further enhanced by clear illustrations and the convenient organization of contributions under separate section headings.
每一期《欧洲泌尿学》都包含20到30篇关于广泛的泌尿学问题的原创文章。精心挑选的同行评审文章提供有关肿瘤学、阳痿、不孕症、儿科、结石和泌尿外科等主题的有用信息。最近在技术、仪器、手术和儿科泌尿外科方面取得的进展得到了专题评论和应用研究论文的支持,为读者提供了泌尿学国际发展的完整指南。通过清晰的插图和在单独的章节标题下方便地组织贡献,进一步增强了期刊对所有泌尿科医生的实用参考价值。通过清晰的插图和在单独的章节标题下方便地组织稿件,杂志作为所有泌尿科医生实用参考的价值进一步增强。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
UROLOGY & NEPHROLOGY (泌尿学与肾脏学) 1区 |
1/76 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
192 | 159 | 33 |
引文计数(2018)
文献(2015-2017)
11512次引用
1662篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Urology
|
#1/97
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
研究方向:CRPC Prostate cancer
接受率: 中等(50%命中)
liting7111
影响因子:2.995
ISSN:0028-3940
研究方向:医学-核医学
影响因子:2.324
ISSN:1051-2284
研究方向:医学-核医学
影响因子:3.156
ISSN:1869-1439
研究方向:CLINICAL NEUROLOGY-RADIOLOGY, NUCLEAR MEDICINE & M
影响因子:4.6
ISSN:0150-9861
研究方向:医学-核医学
影响因子:1.764
ISSN:1591-0199
研究方向:CLINICAL NEUROLOGY-RADIOLOGY, NUCLEAR MEDICINE & M
影响因子:4.966
ISSN:0195-6108
研究方向:医学-核医学
影响因子:3.005
ISSN:0301-0449
研究方向:医学-核医学
影响因子:2.396
ISSN:1793-5458
研究方向:OPTICS-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGI
影响因子:3.632
ISSN:1084-9785
研究方向:医学-核医学
发表一篇学和医学成像类SCI论文
需要多少钱?
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
EUROPEAN UROLOGY 投稿经验
(由下方点评分析获得,2人参与,12967人阅读)